Year: 2020

BERGENBIO ASA: RESULTS FOR THE FIRST QUARTER 2020

May 19, 2020

Bergen, Norway, 19 May 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…

Read More

BERGENBIO RAISES NOK500m (€45.4m) VIA AN OVER SUBSCRIBED PRIVATE PLACEMENT

May 5, 2020

Bergen, Norway, 5 May 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel,…

Read More

BERGENBIO ASA – PRIVATE PLACEMENT SUCCESSFULLY PLACED

May 4, 2020

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES, OR IN…

Read More

BerGenBio ASA – Contemplated Private Placement

May 4, 2020

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES, OR IN…

Read More

BERGENBIO’S BEMCENTINIB SELECTED TO BE FAST-TRACKED AS POTENTIAL TREATMENT FOR COVID-19 THROUGH NEW NATIONAL UK GOVERNMENT CLINICAL TRIAL INITIATIVE

April 28, 2020

Bemcentinib selected as first candidate to be tested through new ACCORD studyThe Phase II clinical…

Read More

BERGENBIO PROVIDES COVID-19 IMPACT ASSESSMENT

March 27, 2020

Bergen, Norway, 27 March 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel,…

Read More